Loading...
Market
How many individuals will be diagnosed with RNU4-2 variant related NDD by end of 2024?
2
Resolution / Starting Odds
Less than 500 • 25%
500-1000 • 25%
1001-1500 • 25%
More than 1500 • 25%
Genetic research publications or health organization reports
Story
Nature Study Links RNU4-2 Variants to 0.4% of Neurodevelopmental Disorders
Jul 12, 2024, 01:08 AM
A groundbreaking study published in Nature has identified de novo variants in the RNU4-2 snRNA as a frequent cause of neurodevelopmental disorders (NDD). The research highlights that mutations in the RNU4-2 gene, a non-coding gene encoding a small nuclear RNA (snRNA), are linked to a significant number of NDD cases, explaining up to 0.4% of these disorders. Notably, the de novo variants, which involve a stretch of 18 bp, were all found on the maternal allele. This discovery marks a landmark moment in the history of NDD genetics, with hundreds of individuals already diagnosed with severe developmental delays due to these mutations.
View original story
Similar markets
Less than 100 patients • 25%
100 to 500 patients • 25%
501 to 1000 patients • 25%
More than 1000 patients • 25%
Yes • 50%
No • 50%
0-10 • 25%
11-50 • 25%
51-100 • 25%
101+ • 25%
0-1000 • 25%
1001-5000 • 25%
5001-10000 • 25%
10001+ • 25%
0-10 patients • 33%
11-20 patients • 33%
More than 20 patients • 33%
1-5 treatments • 25%
6-10 treatments • 25%
11-15 treatments • 25%
More than 15 treatments • 25%
Severe Combined Immunodeficiency • 25%
Long QT Syndrome • 25%
Cystic Fibrosis • 25%
Other • 25%
Increase in rates • 25%
Decrease in rates • 25%
No change • 25%
Data not available • 25%
Increase among children • 25%
Increase among young adults • 25%
Increase among racial/ethnic minorities • 25%
Decrease overall • 25%
Less than 200 • 25%
200-299 • 25%
300-399 • 25%
400 or more • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
21+ • 25%
